Skip to content

Optimizing Mental Health for Young People at Clinical High Risk for Psychosis (CHR)

Optimizing Mental Health for Young People at Clinical High Risk for Psychosis (CHR)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05757128
Enrollment
30
Registered
2023-03-07
Start date
2023-08-24
Completion date
2024-12-19
Last updated
2025-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis, Psychosocial Functioning

Brief summary

This proposal aims to adapt an evidence-based comprehensive psychosocial and mental health support program, the Optimal Health Program (OHP), to improve functioning, reduce distress, and build resiliency in youth who are at clinical risk of developing psychosis (CHR). The main aims of the studies are 1). To adapt an existing, effective, validated psychological intervention for use in young people with CHR; 2). To evaluate the acceptability of OHP and the feasibility of conducting a clinical trial of OHP in individuals with CHR; 3). To assess the preliminary efficacy of OHP in enhancing resiliency, reducing depression and anxiety, and improving functioning in individuals with CHR in a single-arm exploratory clinical trial. Participants will be delivered OHP intervention over 12-weeks. Measures will be completed at study entry and repeated immediately post-treatment at 12-weeks.

Interventions

The OHP intervention will comprise a psychosocial management program that will be adapted to the CHR population and will be accompanied by a structured workbook. Sessions are approximately 1 hour in duration and held weekly for 6 weeks, and every two weeks for the remaining 6 weeks. The OHP has three components: 1) assessment and engagement; 2) therapy sessions, and 3) maintenance integration.

Sponsors

Centre for Addiction and Mental Health
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 29 Years
Healthy volunteers
No

Inclusion criteria

1. Be 16-29 years old 2. Being competent and willing to consent to study participation 3. Meets CHR criteria for a psychosis risk syndrome based on the Structured Interview for Psychosis Risk Syndromes (SIPS) either currently or at some point in the past 3 years.

Exclusion criteria

1. Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of psychotic disorder (e.g., schizophrenia spectrum disorder, mood disorder with psychotic features) 2. Diagnosis of intellectual disability previously documented in the patient chart 3. Severe developmental disorder 4. Acute suicidality requiring immediate intervention

Design outcomes

Primary

MeasureTime frameDescription
Client Satisfaction Questionnairepost treatment (12 weeks after baseline)A Likert scale from 1-4, total scores range from 8-32, with higher scores indicating greater satisfaction.
Adherencepost treatment (12 weeks after baseline)Percent sessions attended.
Retention ratespost treatment (12 weeks after baseline)Percent participants who complete 12-week sessions.
Attritionpost treatment (12 weeks after baseline)Percent participants that dropout at 12-weeks

Secondary

MeasureTime frameDescription
Structured Interview for Prodromal Symptomsbaseline and post treatment (12 weeks after baseline)The Structured Interview for Prodromal Symptoms (SIPS) is a widely used structured interview for diagnosing a CHR syndrome for psychosis and cases of first episode psychosis. It contains a severity rating scale (the Scale Of Psychosis-risk Symptoms, or SOPS). It is a 6-point scale, with higher scores indicating higher severity.
Calgary Depression Scale for Schizophreniabaseline and post treatment (12 weeks after baseline)This scale measures the severity of depression symptoms. It is of a 4-point likert type scale with nine items with higher score indicating higher severity.
Global Functioning: Socialbaseline and post treatment (12 weeks after baseline)This is a brief clinician-administered measures of social functioning, administered as a semi-structured interview with detailed anchors for ratings that address social functioning difficulties typically experienced by youth at risk for psychosis. Total possible scores on either scale ranges from 1 to 10, with higher scores indicating better social functioning.
Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)baseline and post treatment (12 weeks after baseline)The MCCB includes ten tests that assess seven cognitive domains: (1) Speed of Processing; (2) Attention/Vigilance; (3) Working Memory; (4) Verbal Learning; (5) Visual Learning; (6) Reasoning and Problem Solving; and (7) Social Cognition. Requires in person administration for standardization. The test generates a raw score and a T score. Higher scores indicate better cognitive performance.
State and trait anxiety inventorybaseline and post treatment (12 weeks after baseline)This is a psychological inventory that measures anxiety. It consists of a 4-point likert scale with 40 items with higher scores indicating higher severity.
Global Functioning: Rolebaseline and post treatment (12 weeks after baseline)This is a brief clinician-administered measures of role functioning, administered as a semi-structured interview with detailed anchors for ratings that address role functioning difficulties typically experienced by youth at risk for psychosis. Total possible scores on either scale ranges from 1 to 10, with higher scores indicating better role functioning.
Psychiatric diagnosesbaseline and post treatment (12 weeks after baseline)Psychiatric diagnoses will be confirmed using the Structured Clinical Interview (SCID) for DSM-5.
Connor-Davidson Resilience Scalebaseline and post treatment (12 weeks after baseline)This is a 25-item self-report rating scale designed to assess resilience, with higher scores indicating better outcome. Each item is rated on a 5-point scale ranging from not true at all or zero to true nearly all of the time or four. The total possible scores range from 0-100.

Other

MeasureTime frameDescription
The Self-report World Health Organization - Disability Assessment Schedule (WHO-DAS 2.0)baseline and post treatment (12 weeks after baseline)A 12-item generic assessment self-administered instrument for health and disability. It consists of a 5-point likert scale with higher scores indicating higher severity of disability.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 8, 2026